XTX Topco Ltd Decreases Stock Position in Geron Co. (NASDAQ:GERN)

XTX Topco Ltd trimmed its position in shares of Geron Co. (NASDAQ:GERN) by 69.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,915 shares of the biopharmaceutical company’s stock after selling 24,506 shares during the quarter. XTX Topco Ltd’s holdings in Geron were worth $50,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. National Bank of Canada FI lifted its stake in shares of Geron by 1,200.0% in the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 6,000 shares in the last quarter. Readystate Asset Management LP acquired a new position in shares of Geron during the 3rd quarter worth approximately $58,000. Rovin Capital UT ADV purchased a new stake in shares of Geron in the third quarter valued at approximately $62,000. CIBC Asset Management Inc increased its holdings in shares of Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 3,805 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in Geron during the third quarter worth $67,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Trading Down 4.6 %

Shares of NASDAQ GERN opened at $3.49 on Monday. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.11 billion, a PE ratio of -10.91 and a beta of 0.51. Geron Co. has a twelve month low of $1.64 and a twelve month high of $5.34. The stock has a fifty day simple moving average of $4.02 and a 200-day simple moving average of $4.35.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.05. The business had revenue of $28.27 million for the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business’s quarterly revenue was up 17138.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.08) earnings per share. On average, equities analysts forecast that Geron Co. will post -0.25 earnings per share for the current year.

Wall Street Analyst Weigh In

GERN has been the topic of several analyst reports. Leerink Partnrs upgraded Geron to a “strong-buy” rating in a report on Monday, September 9th. Barclays upgraded shares of Geron to a “strong-buy” rating in a report on Friday, November 29th. Scotiabank initiated coverage on shares of Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Geron in a report on Tuesday, December 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Geron in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Geron currently has an average rating of “Moderate Buy” and a consensus target price of $7.15.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.